Third Quarter 2023 Financial Results

Nasdaq: EXEL
Today’s Agenda

Introduction
Susan Hubbard
EVP, Public Affairs & Investor Relations

Third Quarter 2023 Highlights
Michael M. Morrissey, Ph.D.
President and CEO

Financial Results & Guidance
Chris Senner
EVP and CFO

Commercial Update
PJ Haley
EVP, Commercial

Development Update
Amy Peterson, M.D.
EVP, Product Development & Medical Affairs and CMO

Pipeline & Discovery Update
Dana T. Aftab, Ph.D.
EVP, Discovery & Translational Research and CSO

Q&A
All, joined by:
Peter Lamb, Ph.D.
EVP, Scientific Strategy
Safe Harbor Statement

This presentation, including any oral presentation accompanying it, contains forward-looking statements, including, without limitation, statements related to: Exelixis’ expectation for the caboza(z)tinib franchise to continue to grow while advancing a range of discovery and development programs to build the Exelixis pipeline of the future; Exelixis’ top R&D priority to deliver clinically and commercially differentiated medicines for large populations of cancer patients with high unmet medical need that may benefit from those medicines; Exelixis’ plans to highlight its integrated strategy spanning drug discovery, development and commercialization activities at its R&D Day in December 2023, as well as elaborate on multiple opportunities to both serve more patients and generate sustainable, long-term value for shareholders; Exelixis’ BD efforts to access assets with potential to generate differentiated clinical data in solid tumor indications; Exelixis’ belief that clinical trial sales may continue to be choppy between quarters; Exelixis’ commitment to repurchase up to $550 million of its common stock before the end of 2023; Exelixis’ updated 2023 financial guidance; the beliefs of physicians and other prescribers that the favorable toxicity profile, QoL and low discontinuation rate experienced with the combination of CABOMETYX and nivolumab can enable patients to remain on therapy longer and potentially achieve long-term survival; Exelixis’ belief that the CONTACT-02 and CABINET studies could provide the opportunity for the continued growth for CABOMETYX in the coming years; Exelixis’ plans to discuss a potential regulatory submission for the combination of caboza(z)tinib and atezolizumab in mCRPC with the FDA when the OS results from CONTACT-02 are more mature, as well as present detailed findings from CONTACT-02 at a future medical meeting; Exelixis’ plans to discuss findings from CABINET with the FDA once the data are in-house; Exelixis’ development plans for zanazarbin and STELLAR-305, including with respect to the amendment to the pivotal trial design for STELLAR-303 to increase the probability of success, as well as the potential for data from the early-stage trials to support expanded development opportunities for zanazarbin; Exelixis’ plans to present data from the ccRCC expansion cohort of STELLAR-001 at the 2023 ICICS; Exelixis’ plans to initiate additional pivotal studies of zanazarbin as part of a broad development program that will address patients with unmet need, including the initiation of STELLAR-305, which will evaluate the combination of zanazarbin and pembrolizumab in certain sCCHN patients and may provide opportunity to improve outcomes compared with single-agent pembrolizumab and offer patients a chemo-free option; Exelixis’ development plans for XB002, including leveraging the various dosing and combinations in the ongoing EWE-101 study to inform future registrational trials; Exelixis’ expectation it will complete the transfer of obligations for XL309 from Insilico by the end of 2023 and belief that XL309 is a potentially best-in-class small molecule inhibitor of USP1, with the potential to broaden the addressable patient population beyond those who carry a BCRA mutation; Exelixis’ beliefs regarding the therapeutic potential of three biotherapeutics DCs (XB010, XB371 and XB628) and that it is on track to file INDs for each of them in mid-to-late 2024; the potential for XL495 to be a best-in-class small molecule inhibitor of PKMYT1 and Exelixis’ expectation for an IND filing in mid-2024; Exelixis’ belief that it is on track to achieve its stated goal of advancing up to five new DCs total during 2023, including from both biotherapeutics and small molecules programs, and the potential for those programs to meaningfully contribute towards Exelixis’ mission; and Exelixis’ list of anticipated milestones for 2023. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved; complexity and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis’ continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating caboza(z)tinib and other Exelixis product candidates; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of its products and product candidates; Exelixis’ ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis’ marketed products; changes in economic and business conditions; and other factors detailed from time to time under the caption “Risk Factors” in Exelixis’ most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis’ other future filings with the Securities and Exchange Commission (SEC). All forward-looking statements in this presentation are based on information available to Exelixis as of the date of this presentation, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

This presentation includes certain non-GAAP financial measures as defined by the SEC rules. As required by Regulation G, we have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in the appendix.
Third Quarter 2023 Highlights

Michael M. Morrissey, Ph.D.
President and CEO
Active Third Quarter 2023 Across All Components of Exelixis Business

Strong cabozantinib performance with continued growth in demand and revenue

- CABOMETYX® maintained status as leading TKI in RCC
- Cabozantinib franchise Q3 2023 NPR: ~$426M in U.S. and ~$586M globally, generated by Exelixis and partners

Prioritizing pipeline of clinically and commercially differentiated medicines for large populations of cancer patients with high unmet medical need

- R&D Day on December 12th in New York City: highlight integrated R&D strategy spanning drug discovery, development and commercialization
- Plan to elaborate on multiple opportunities to both serve more patients and generate sustainable, long-term value for Exelixis shareholders

BD efforts focused on accessing potentially differentiated clinical-stage assets

- In September, announced exclusive, global license agreement with Insilico Medicine for XL309, a small molecule inhibitor of USP1, an emerging synthetic lethal target in BRCA-mutated tumors

MSN II cabozantinib intellectual property trial took place Oct. 23-26 at U.S. District Court in Delaware
Q3’23 Total Revenues  
(See press release at www.exelixis.com for full details)

Amounts may not sum due to rounding.

<table>
<thead>
<tr>
<th></th>
<th>Q3’22</th>
<th>Q4’22</th>
<th>Q1’23</th>
<th>Q2’23</th>
<th>Q3’23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cometriq</td>
<td>$361.4M</td>
<td>$372.6M</td>
<td>$361.8M</td>
<td>$403.3M</td>
<td>$422.2M</td>
</tr>
<tr>
<td>Cabometyx</td>
<td>$5.1M</td>
<td>$4.9M</td>
<td>$1.6M</td>
<td>$6.4M</td>
<td>$4.3M</td>
</tr>
<tr>
<td>License Revenues</td>
<td>$34.4M</td>
<td>$38.1M</td>
<td>$38.3M</td>
<td>$52.7M</td>
<td>$42.4M</td>
</tr>
<tr>
<td>Collaboration Services Revenues</td>
<td>$0.9M</td>
<td>$8.4M</td>
<td>$7.1M</td>
<td>$7.5M</td>
<td>$3.1M</td>
</tr>
</tbody>
</table>

**Q3’23 Notes**

- $426.5M in net product revenues
- Q3’23 license revenues include cabozantinib royalties to Exelixis of $37.8M
- Q3’23 collaboration services revenues primarily consist of development cost reimbursements from Ipsen and Takeda
### Q3’23 R&D Expenses
*(See press release at www.exelixis.com for full details)*

<table>
<thead>
<tr>
<th></th>
<th>Q3’22</th>
<th>Q4’22</th>
<th>Q1’23</th>
<th>Q2’23</th>
<th>Q3’23</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Other R&amp;D Expenses</strong></td>
<td>170.6</td>
<td>177.0</td>
<td>186.3</td>
<td>206.1</td>
<td>216.7</td>
</tr>
<tr>
<td><strong>License and Other Collaboration Costs</strong></td>
<td>16.4</td>
<td>16.5</td>
<td>3.3</td>
<td>9.6</td>
<td>12.4</td>
</tr>
<tr>
<td><strong>Stock-Based Compensation</strong></td>
<td>16.4</td>
<td>16.5</td>
<td>44.7</td>
<td>16.9</td>
<td>103.5</td>
</tr>
</tbody>
</table>

**Amounts may not sum due to rounding.**

A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.

*License and other collaboration costs include upfront, program initiation, development milestone fees, and other fees; in-process research and development assets acquired; and R&D funding for our collaboration and licensing agreements and assets purchase agreements.

### Q3’23 Notes

- GAAP R&D expenses of $332.6M
- Increase in R&D expenses vs. Q2’23 primarily due to higher license and other collaboration costs
- License and other collaboration costs includes a $80.0M upfront payment to Insilico Medicine
- Non-GAAP R&D expenses of $320.1M (excludes stock-based compensation expenses, before tax effect)
Q3’23 SG&A Expenses
(See press release at www.exelixis.com for full details)

GAAP SG&A expenses of $138.1M
Decrease in GAAP SG&A expenses vs. Q2’23 primarily due to lower legal and advisory fees related to the recent proxy contest partially offset by higher stock-based compensation
Non-GAAP SG&A expenses of $110.1M (excludes stock-based compensation expenses, before tax effect)

Amounts may not sum due to rounding.
A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.
Q3’23 Net Income (Loss)
(See press release at www.exelixis.com for full details)

A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.

Q3’23 Notes

- GAAP net income of $1.0M
- Decrease in GAAP net income vs. Q2’23 primarily due to higher license and other collaboration costs, including the $80.0M upfront payment to Insilico Medicine
- Non-GAAP net income of $32.1M (excludes stock-based compensation expenses, net of tax effect)
Q3’23 Diluted Earnings (Loss) Per Share
(See press release at www.exelixis.com for full details)

<table>
<thead>
<tr>
<th></th>
<th>GAAP diluted EPS</th>
<th>Non-GAAP diluted EPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3’22</td>
<td>0.23</td>
<td>0.31</td>
</tr>
<tr>
<td>Q4’22</td>
<td>(0.09)</td>
<td>0.03</td>
</tr>
<tr>
<td>Q1’23</td>
<td>0.12</td>
<td>0.16</td>
</tr>
<tr>
<td>Q2’23</td>
<td>0.25</td>
<td>0.31</td>
</tr>
<tr>
<td>Q3’23</td>
<td>0.00</td>
<td>0.10</td>
</tr>
</tbody>
</table>

A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.
## GAAP Financial Highlights: Q3’23
*(in millions, except per share amounts)*

<table>
<thead>
<tr>
<th></th>
<th>Q3’22</th>
<th>Q2’23</th>
<th>Q3’23</th>
<th>YoY Delta</th>
<th>QoQ Delta</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues</td>
<td>$411.7 M</td>
<td>$469.8 M</td>
<td>$471.9 M</td>
<td>+15%</td>
<td>+0%</td>
</tr>
<tr>
<td>Cost of goods sold</td>
<td>$15.3 M</td>
<td>$17.7 M</td>
<td>$18.8 M</td>
<td>+23%</td>
<td>+6%</td>
</tr>
<tr>
<td>R&amp;D expenses</td>
<td>$198.8 M</td>
<td>$232.6 M</td>
<td>$332.6 M</td>
<td>+67%</td>
<td>+43%</td>
</tr>
<tr>
<td>SG&amp;A expenses</td>
<td>$115.0 M</td>
<td>$141.7 M</td>
<td>$138.1 M</td>
<td>+20%</td>
<td>-3%</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>$329.1 M</td>
<td>$392.0 M</td>
<td>$489.5 M</td>
<td>+49%</td>
<td>+25%</td>
</tr>
<tr>
<td>Other income, net</td>
<td>$9.4 M</td>
<td>$22.5 M</td>
<td>$23.4 M</td>
<td>+148%</td>
<td>+4%</td>
</tr>
<tr>
<td>Income tax provision</td>
<td>$18.8 M</td>
<td>$19.2 M</td>
<td>$4.8 M</td>
<td>-75%</td>
<td>-75%</td>
</tr>
<tr>
<td>Net income</td>
<td>$73.2 M</td>
<td>$81.2 M</td>
<td>$1.0 M</td>
<td>-99%</td>
<td>-99%</td>
</tr>
<tr>
<td>Net income per share, diluted</td>
<td>$0.23</td>
<td>$0.25</td>
<td>$0.00</td>
<td>-100%</td>
<td>-100%</td>
</tr>
<tr>
<td>Ending cash and investments</td>
<td>$2,100.2 M</td>
<td>$2,105.4 M</td>
<td>$1,915.1 M</td>
<td>-9%</td>
<td>-9%</td>
</tr>
</tbody>
</table>

*Amounts may not sum due to rounding.*

(1) Cash and Investments is composed of cash, cash equivalents, restricted cash equivalents and investments. Since Q2’23, there are no restrictions on cash, cash equivalents and investments.
2023 Share Repurchase Program Activity  
*(in millions, except per share amounts)*

<table>
<thead>
<tr>
<th></th>
<th>Amount Repurchased</th>
<th>Shares Repurchased</th>
<th>Average Purchase Price per Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 2023</td>
<td>$127.0</td>
<td>6.608</td>
<td>$19.22</td>
</tr>
<tr>
<td>Q3 2023</td>
<td>$217.8</td>
<td>10.335</td>
<td>$21.08</td>
</tr>
<tr>
<td>Total</td>
<td>$344.8</td>
<td>16.943</td>
<td>$20.35</td>
</tr>
</tbody>
</table>

*$550M share repurchase program authorized in March 2023, with $205.2M remaining as of September 30, 2023.*
## Full Year 2023 Financial Guidance*

<table>
<thead>
<tr>
<th></th>
<th>Current Guidance (Provided November 1, 2023)</th>
<th>Previous Guidance (Provided January 8, 2023)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenues</td>
<td>$1.825B - $1.850B</td>
<td>$1.775B - $1.875B</td>
</tr>
<tr>
<td>Net Product Revenues</td>
<td>$1.625B - $1.650B</td>
<td>$1.575B - $1.675B</td>
</tr>
<tr>
<td>Cost of Goods Sold</td>
<td>4% - 5% of net product revenues</td>
<td>4% - 5% of net product revenues</td>
</tr>
<tr>
<td>R&amp;D Expenses</td>
<td>$1.050B - $1.075B</td>
<td>$1.000B - $1.050B</td>
</tr>
<tr>
<td></td>
<td>Includes $35M of non-cash stock-based</td>
<td>Includes $45M of non-cash stock-based</td>
</tr>
<tr>
<td></td>
<td>compensation expense</td>
<td>compensation expense</td>
</tr>
<tr>
<td>SG&amp;A Expenses</td>
<td>$525M - $550M</td>
<td>$475M - $525M</td>
</tr>
<tr>
<td></td>
<td>Includes $70M of non-cash stock-based</td>
<td>Includes $55M of non-cash stock-based</td>
</tr>
<tr>
<td></td>
<td>compensation expense</td>
<td>compensation expense</td>
</tr>
<tr>
<td>Effective Tax Rate</td>
<td>20% - 22%</td>
<td>20% - 22%</td>
</tr>
</tbody>
</table>

*The financial guidance above reflects U.S. GAAP amounts.
Commercial Update

PJ Haley
EVP, Commercial
CABOMETYX: Q3 2023 Performance

Strong execution continued in Q3 2023

- $426.5M in franchise net product revenues
- Strong demand and new patient starts continue to drive growth

CABOMETYX remains the #1 prescribed TKI in RCC and 2L HCC

CheckMate -9ER 44-month follow-up data (ASCO GU 2023) continues to resonate with prescribers

- Compelling CABOMETYX + nivolumab combination median OS of 49.5 months
- Combination improved median OS by 14 months relative to sunitinib

CABOMETYX + nivolumab remains the #1 prescribed TKI + IO in 1L RCC
CABOMETYX Business Summary - #1 TKI in RCC

CABOMETYX continues to lead TRx market with over 38% share in Q3’23

- Broad uptake in the 1L RCC setting across clinical risk groups and practice settings
- Prescriber experience continues to be very positive

CABOMETYX in combination with nivolumab is the #1 prescribed TKI+IO regimen in 1L RCC

- 8% YoY TRx volume growth (Q3’23 vs. Q3’22)

**TRx Market Share**

<table>
<thead>
<tr>
<th></th>
<th>Q3’22</th>
<th>Q3’23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutent</td>
<td>37.5%</td>
<td>38.3%</td>
</tr>
<tr>
<td>Votrient</td>
<td>24.0%</td>
<td>22.3%</td>
</tr>
<tr>
<td>Lenvima</td>
<td>21.5%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Inlyta</td>
<td>10.0%</td>
<td>8.8%</td>
</tr>
<tr>
<td>Cabometyx</td>
<td>7.1%</td>
<td>6.9%</td>
</tr>
</tbody>
</table>

$361.4M* $422.2M*

*CABOMETYX net product revenues

TKI = tyrosine kinase inhibitor
RCC = renal cell carcinoma
TRx = total prescriptions
1L = first-line
IO = immunotherapy

Source for TRx: IQVIA National Prescription Audit 9/30/23, including Cabometyx, Inlyta, Sutent, Votrient, Lenvima; includes scripts across indications. Sutent includes volumes from generic. Amounts in chart may not sum to 100% due to rounding.
CheckMate -9ER 44-month Follow-up OS Data Continue to Drive Meaningful Differentiation for CABOMETYX + Nivolumab vs. TKI+IO Competition

**Median OS over 4 years for CABOMETYX + nivolumab**

- Prescribers are compelled by the median OS of 49.5 months of the combination
- CABOMETYX improved median OS by 14 months relative to sunitinib
- The CheckMate -9ER 44-month follow-up OS data are viewed as clinically meaningful and differentiating by oncologists

**Median OS of 49.5 months for CABOMETYX + nivolumab supports balance of data**

- Prescribers believe that long-term survival may be achieved due to the ability to remain on therapy
- Physicians believe favorable toxicity profile, quality of life, and low discontinuation rate enable patients to remain on therapy

---

**TKI** = tyrosine kinase inhibitor  
**IO** = immunotherapy  
**aRCC** = advanced renal cell carcinoma  
**OS** = overall survival

---

1L = first-line
CABOMETYX + Nivolumab: The #1 Prescribed TKI+IO Combination in 1L RCC

CABOMETYX + nivolumab remains the #1 prescribed 1L RCC TKI+IO combination therapy for a fourth consecutive quarter

Prescriber clinical experience continues to reflect the balance of superior efficacy, safety and tolerability, and QoL demonstrated in the CheckMate -9ER study

• 44-month follow-up data reinforce physician experience

CheckMate -9ER 44-month follow-up data: long-term OS now exceeds 4 years

• Prescribers are compelled by the median OS of 49.5 months for the combination of CABOMETYX + nivolumab, 14 months longer than sunitinib arm

Sources:
Internal Exelixis data
IQVIA National Prescription Audit and BrandImpact data through 9/30/23

TKI = tyrosine kinase inhibitor
IO = immunotherapy
RCC = renal cell carcinoma
QoL = quality of life
OS = overall survival
Development Update

Amy Peterson, M.D.
EVP, Product Development & Medical Affairs and CMO
Cabozantinib

2\textsuperscript{nd}-generation TKI targeting MET/VEGFR/AXL/MER
Positive Cabozantinib Phase 3 Data Readouts in Third Quarter 2023

**CONTACT-02**

1L/2L mCRPC

**Key Endpoints**
- **Primary:** BICR-PFS, OS
- **Secondary:** BIRC-ORR, DOR, PSA

**CABINET**

2L pNET and epNET

**Key Endpoints**
- **Primary:** BICR-PFS
- **Secondary:** OS, ORR, Safety

**CONTACT-02:** Pivotal phase 3 study of cabozantinib + atezolizumab vs. 2\(^{nd}\) NHT in patients with previously treated mCRPC

- Top-line press release announcing positive results on August 21\(^{st}\)

**CABINET:** Pivotal phase 3 study conducted by The Alliance for Clinical Trials in Oncology evaluating cabozantinib vs. placebo in patients with advanced pNET and advanced epNET

- Top-line press release announcing positive results on August 24\(^{th}\)
- Data presented by Dr. Jennifer Chan at 2023 ESMO Congress on October 22\(^{nd}\)

**CONTACT-02**

**CABINET**

**CONTACT-02:** Pivotal phase 3 study of cabozantinib + atezolizumab vs. 2\(^{nd}\) NHT in patients with previously treated mCRPC

- Top-line press release announcing positive results on August 21\(^{st}\)

**CABINET:** Pivotal phase 3 study conducted by The Alliance for Clinical Trials in Oncology evaluating cabozantinib vs. placebo in patients with advanced pNET and advanced epNET

- Top-line press release announcing positive results on August 24\(^{th}\)
- Data presented by Dr. Jennifer Chan at 2023 ESMO Congress on October 22\(^{nd}\)

**CONTACT-02**

**CABINET**

**CONTACT-02:** Pivotal phase 3 study of cabozantinib + atezolizumab vs. 2\(^{nd}\) NHT in patients with previously treated mCRPC

- Top-line press release announcing positive results on August 21\(^{st}\)

**CABINET:** Pivotal phase 3 study conducted by The Alliance for Clinical Trials in Oncology evaluating cabozantinib vs. placebo in patients with advanced pNET and advanced epNET

- Top-line press release announcing positive results on August 24\(^{th}\)
- Data presented by Dr. Jennifer Chan at 2023 ESMO Congress on October 22\(^{nd}\)

**CONTACT-02**

**CABINET**

**CONTACT-02:** Pivotal phase 3 study of cabozantinib + atezolizumab vs. 2\(^{nd}\) NHT in patients with previously treated mCRPC

- Top-line press release announcing positive results on August 21\(^{st}\)

**CABINET:** Pivotal phase 3 study conducted by The Alliance for Clinical Trials in Oncology evaluating cabozantinib vs. placebo in patients with advanced pNET and advanced epNET

- Top-line press release announcing positive results on August 24\(^{th}\)
- Data presented by Dr. Jennifer Chan at 2023 ESMO Congress on October 22\(^{nd}\)
Positive CONTACT-02 Results Announced on August 21, 2023

CONTACT-02: Pivotal phase 3 study of cabozantinib + atezolizumab vs. 2\textsuperscript{nd} NHT in patients with previously treated mCRPC

- Statistically significant PFS benefit for cabo+atezo and favorable trend in OS
- No new safety signals and AEs consistent with cabo or atezo monotherapy
- Plan to discuss potential regulatory submission when OS results are more mature, based on feedback from FDA

**CONTACT-02**

**Metastatic CRPC**
- Measurable visceral disease or extrapelvic adenopathy
- 1 prior NHT

**Key Endpoints**
- **Primary:** BICR-PFS, OS
- **Secondary:** BICR-ORR, DOR, PSA

**Detailed findings to be presented at a future medical meeting**
Positive CABINET Results Presented at 2023 ESMO Congress

CABINET: Pivotal phase 3 study conducted by The Alliance for Clinical Trials in Oncology evaluating cabozantinib vs. placebo in patients with advanced pNET and epNET

- Top-line press release announcing positive results on August 24th
- Data presented by Dr. Jennifer Chan at 2023 ESMO Congress:
  - pNET PFS HR: 0.27; pNET median PFS of 11.4 months vs. 3.0 months
  - epNET PFS HR: 0.45; epNET median PFS of 8.3 months vs. 3.2 months
  - No new safety signals identified for cabozantinib

Plan to discuss results with FDA once data are in-house

**Key Endpoints per Cohort**
- **Primary:** BICR-PFS
- **Secondary:** OS, ORR, Safety

**2L pNET and epNET**

- **pNET Cohort**
  - Cabozantinib vs. placebo

- **epNET Cohort**
  - Cabozantinib vs. placebo

2L = second-line  
PFS = progression-free survival  
OS = overall survival  
ORR = objective response rate  
FDA = U.S. Food and Drug Administration  
HR = hazard ratio  
pNET = pancreatic neuroendocrine tumors  
epNET = extra-pancreatic neuroendocrine tumors  
ESMO = European Society for Medical Oncology  
BICR = blinded independent central radiology review
Zanzalintinib

3rd-generation TKI targeting MET/VEGFR/AXL/MER
### STELLAR-001/002: Phase 1b/2 Studies of Zanzalintinib ± ICI Combinations

*Exelixis-sponsored Trials in Collaboration with Genentech/Roche and Bristol Myers Squibb*

#### STELLAR-001 (Phase 1b/2)
- Study of zanzalintinib monotherapy or in combination with atezolizumab in advanced/metastatic solid tumors
- Status: Ongoing

<table>
<thead>
<tr>
<th>Expansion Cohorts</th>
</tr>
</thead>
<tbody>
<tr>
<td>ccRCC</td>
</tr>
<tr>
<td>nccRCC</td>
</tr>
<tr>
<td>HR+ BC</td>
</tr>
<tr>
<td>mCRPC</td>
</tr>
<tr>
<td>CRC</td>
</tr>
</tbody>
</table>

#### STELLAR-002 (Phase 1b/2)
- Study of zanzalintinib in combination with IO agents in subjects with advanced or metastatic solid tumors
- Status: Ongoing

<table>
<thead>
<tr>
<th>Expansion Cohorts</th>
</tr>
</thead>
<tbody>
<tr>
<td>ccRCC (1L, 2L)</td>
</tr>
<tr>
<td>nccRCC (1L)</td>
</tr>
<tr>
<td>HCC (1L)</td>
</tr>
<tr>
<td>NSCLC (1L low PD-L1, 2L+)</td>
</tr>
<tr>
<td>HNSCC (ICI-naive)</td>
</tr>
<tr>
<td>mCRPC (2L post-NHT)</td>
</tr>
<tr>
<td>MSS mCRC (2L+)</td>
</tr>
<tr>
<td>UC (prior ICI, no prior ICI)</td>
</tr>
</tbody>
</table>

#### Dose Escalation

<table>
<thead>
<tr>
<th>STELLAR-001 (Phase 1b/2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanzalintinib</td>
</tr>
<tr>
<td>Zanzalintinib + Atezolizumab</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STELLAR-002 (Phase 1b/2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanza + Nivolumab</td>
</tr>
<tr>
<td>Zanza + Nivolumab + Ipilimumab</td>
</tr>
<tr>
<td>Zanza + Nivolumab + Relatlimab</td>
</tr>
</tbody>
</table>

**Key Terms**
- **1L = first-line**
- **2L = second-line**
- **IO = immunotherapy**
- **ccRCC = clear cell renal cell carcinoma**
- **nccRCC = non-clear cell RCC**
- **mCRC = metastatic castration-resistant prostate cancer**
- **mCRPC = metastatic castration-resistant prostate cancer**
- **HNSCC = squamous cell carcinoma of the head and neck**
- **HR+ BC = hormone receptor positive breast cancer**
- **UC = urothelial carcinoma**
- **ICI = immune checkpoint inhibitor**
- **PD-L1 = programmed death-ligand 1**
- **HCC = hepatocellular carcinoma**
- **MSS = microsatellite stable**
- **NSCLC = non-small cell lung cancer**
- **mCRC = metastatic colorectal cancer**
- **HCC = hepatocellular carcinoma**
- **ICI = immune checkpoint inhibitor**
- **PD-L1 = programmed death-ligand 1**
Zanzalintinib: STELLAR-001 ccRCC Expansion Cohort to be presented at 2023 IKCS

Zanzalintinib (XL092)

- Next-generation, multi-targeted TKI
- Similar kinase inhibition profile to cabozantinib, with shorter clinical half-life
- Encouraging data presented at ESMO 2022 supports broad development

Ongoing Clinical Trials

Phase 1b/2: STELLAR-001
Phase 1b/2: STELLAR-002
Phase 3: STELLAR-303
Phase 3: STELLAR-304

Previously disclosed: Early, promising data from ccRCC cohort

- 2L+ ccRCC expansion cohort: 32 patients at 100 mg starting dose
- Compelling and durable responses observed in cabozantinib-naïve and cabozantinib-experienced patients
- Emerging safety profile continues to look encouraging
- Data provide evidence for activity of zanzalintinib in cabozantinib-sensitive tumor type, and additional support for leveraging cabozantinib data to inform zanzalintinib development

Complete ccRCC dataset to be presented on Nov. 10th during Oral Abstracts Session at 2023 IKCS
STELLAR-303: Pivotal Study of Zanzalintinib + Atezolizumab in 3L+ CRC
Exelixis-sponsored Trial with Atezolizumab Supplied by Genentech/Roche

STELLAR-303 (Phase 3)

- Study of zanzalintinib + atezolizumab in patients with MSS/MSI-low mCRC who have progressed after or are intolerant to the following SOC therapies: Fluoropyrimidine, irinotecan and oxaliplatin based chemotherapy, +/- VEGFi, and, if RAS wt, anti-EGFR therapy.
- Primary population: non-liver metastases (NLM); pts w/o active LM at screening (by CT/MRI) including LM definitively treated at least 6 months prior to enrollment w/o evidence of progression
- Status: Ongoing

Key Study Objectives
- **Primary:** OS in pts w/o liver metastases
- **Secondary:** OS (full ITT), PFS, ORR

Q2’23: announced protocol amendment to increase probability of success by changing primary endpoint to OS in patients without liver metastases

Experimental Arm
Zanzalintinib + Atezolizumab

Control Arm
Regorafenib

N = 874

OS = overall survival
PFS = progression free survival
ORR = objective response rate
ITT = intent to treat population
w/o = without
pts = patients
3L = third-line
CRC = colorectal cancer
MSS = microsatellite stable
MSI = microsatellite instability
SOC = standard of care
LM = liver metastases
**STELLAR-304: Pivotal Study of Zanzalintinib + Nivolumab in 1L nccRCC**

**Exelixis-sponsored Trial with Nivolumab Supplied by Bristol Myers Squibb**

**STELLAR-304 (Phase 3)**

- A study of zanzalintinib + nivolumab vs. sunitinib in 1L unresectable, advanced or metastatic nccRCC, including papillary, unclassified or translocation-associated histologies
- No prior treatment for nccRCC (adjuvant PD-1 allowed if >6 months ago)
- Status: Ongoing

**Key Study Objectives**

- **Primary:** PFS, ORR per RECIST v1.1
- **Additional:** OS

- **Trial hypothesis based on NCI-sponsored phase 2 study of cabozantinib and phase 2 IST of cabozantinib + nivolumab**
- **Enrollment ongoing in multiple countries**

**Experimental Arm**

Zanzalintinib + Nivolumab

**Control Arm**

Sunitinib

N = 291
STELLAR-305: Pivotal Study of Zanzalintinib + Pembrolizumab in 1L PD-L1+ HNSCC

Exelixis-sponsored Trial

STELLAR-305 (Phase 2/3)

- A study of zanzalintinib + pembro vs. pembro alone in R/M HNSCC incurable by local therapies and no prior systemic therapy for R/M disease
- PD-L1 combined positive score (CPS) ≥ 1 RECIST v1.1 measurable disease
- Status: Initiating

Key Study Objectives

- **Primary:** PFS, OS
- **Additional:** ORR, DOR, QoL, safety and tolerability

• **Supported by data from a Phase 2 IST of cabozantinib + pembrolizumab (Saba, ASCO 2022)**

• **May provide opportunity to improve outcomes vs. single-agent pembro, based on emerging zanza activity + safety profile**
XB002

Next-generation TF-targeting ADC
JEWEL-101 (Phase 1)

- First-in-human phase 1 study of XB002 as a single agent and in combination with IO in advanced or metastatic solid tumors
- Status: Ongoing

**Established RD for single agent XB002 and initiated multiple expansion cohorts. A lower dose is also being carried forward to fulfill FDA’s Project Optimus requirements for dose optimization.**

**Enrollment in dose escalation cohorts for nivolumab and bevacizumab combinations is ongoing.**
XL309
Small molecule USP1 inhibitor
Rationale for XL309: Dual PARP and USP1 Inhibition Enhances Synthetic Lethality in BRCA-mutated Cells

![Diagram showing the mechanism of PARP and USP1 inhibition]

**XL309 Program Status:** anticipating full transfer of obligations from Insilico by YE 2023

**abbreviations:**
- **PARP** = poly ADP ribose polymerase
- **USP1** = ubiquitin specific peptidase 1
- **DSB** = double strand break
- **SSB** = single strand break
- **HR** = homologous recombination

**Key Points:**
- DNA damage (SSBs) leads to base excision repair and DNA repair.
- PARP inhibition results in DNA replication (accumulation of DNA DSBs).
- USP1 inhibition affects DNA lesion repair and tumor-selective cytotoxicity.
- Normal cells with functional HR pathway survive.
- HR-deficient tumor cells (e.g., BRCA1/2mut) have impaired HR-mediated DNA DSB repair, leading to cell death.

**Definitions:**
- **DNA damage** (SSBs) refers to single strand breaks (SSBs) in DNA.
- **PARP** (poly ADP ribose polymerase) plays a role in DNA repair.
- **USP1** (ubiquitin specific peptidase 1) is involved in DNA repair processes.
- **DSB** (double strand break) is a severe form of DNA damage.
- **HR** (homologous recombination) is a DNA repair pathway.
Q3 2023 Development Summary

➢ Advancing robust pipeline of molecules while maximizing potential of cabozantinib to benefit more patients in unmet need indications

➢ Continue to expedite the development of promising pipeline assets into registrational trials for the benefit of patients with cancer

➢ Plan to share more detailed information about progress and recent data at upcoming R&D Day on December 12th in New York City
Pipeline and Discovery Update

Dana T. Aftab, Ph.D.
EVP, Discovery & Translational Research and CSO
On Track to File 4 New IND Applications in 2024

<table>
<thead>
<tr>
<th>Program Name</th>
<th>Mechanism</th>
<th>Discovery / Preclinical</th>
<th>IND</th>
<th>Phase 1a</th>
<th>Phase 1b</th>
<th>Phase 2 / 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanzalintinib (XL092)</td>
<td>Next-generation TKI targeting MET/VEGFR/AXL/MER</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XB002</td>
<td>Next-generation TF-targeting ADC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XL102</td>
<td>Potent, selective, orally bioavailable CDK7 inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBX-12 (Cybrexa)</td>
<td>Novel exatecan peptide-drug conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADU-1805 (Sairopa)</td>
<td>Monoclonal antibody targeting SIRPα</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XL309</td>
<td>Small molecule USP1 inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XB010</td>
<td>Next-generation 5T4-targeting ADC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XB628</td>
<td>Bispecific antibody targeting PD-L1 + NKG2A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XB371</td>
<td>Next-generation TF-Topoisomerase ADC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XL495</td>
<td>Small molecule PKMYT1 inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XB014</td>
<td>Bispecific antibody targeting PD-L1 + CD47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TKI = tyrosine kinase inhibitor
TF = tissue factor
ADC = antibody-drug conjugate
CDK7 = cyclin-dependent kinase 7
SIRPα = signal-regulatory protein alpha
NKG2A = natural killer cell receptor group 2A
PD-L1 = programmed death-ligand 1
CD47 = cluster of differentiation 47
IND = Investigational New Drug status
DC = development candidate
USP1 = ubiquitin specific peptidase 1
PKMYT1 = protein kinase membrane associated tyrosine/threonine 1
XL495: Small Molecule Inhibitor of PKMYT1

**PKMYT1**
- Increased Cyclin E levels cause genome instability and DNA damage across a wide range of tumors including ovarian, endometrial, and colorectal
- PKMYT1 inhibits CDK1, preventing mitotic entry for damaged genomes
- Inhibition of PKMYT1 in cancer cells with high Cyclin E allows mitosis before completion of DNA synthesis, with catastrophic consequences

**XL495**
- Potent and selective small molecule inhibitor of PKMYT1, designed to be best-in-class
- Shows synthetic lethality in preclinical models with increased Cyclin E levels

**XL495 IND filing expected in 2024**
Closing

Michael M. Morrissey, Ph.D.
President and CEO
## Anticipated Milestones for 2023

<table>
<thead>
<tr>
<th>Program</th>
<th>Milestone</th>
</tr>
</thead>
</table>
| Cabozantinib          | ✓ Report top-line results from pivotal trial of cabozantinib + atezolizumab in RCC (CONTACT-03) in 1H 2023  
 ✓ Complete enrollment and report top-line results in pivotal trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02) in 2H 2023  |
| Zanzalintinib         | ❑ Initiate multiple new phase 3 pivotal trials evaluating zanzalintinib across indications, tumor types and novel IO combinations  |
| XB002                 | ❑ Accelerate development of XB002 TF ADC, as a monotherapy and in combination with IO and other targeted therapies, across a wide range of tumor types, with goal of moving into full development  
 ✓ Initiate cohort expansion stage of phase 1 JEWEL-101 study after RD and/or MTD have been determined  |
| XL102                 | ❑ Complete dose escalation, advance phase 1 QUARTZ-101 study into cohort expansion stage and initiate potential combination cohorts  |
| CBX-12 (Cybrexa)      | ✓ Cybrexa expected to continue to advance phase 1 clinical studies of CBX-12 PDC, including dose-expansion cohorts  |
| ADU-1805 (Sairopa)    | ✓ Sairopa to file IND for ADU-1805 SIRPα-targeting monoclonal antibody program in Q1 2023  |
| DCs                   | ✓ Advance XB010 (5T4-targeting ADC), XB628 (PD-L1 x NKG2A bsAb), XB371 (TF-Topoisomerase ADC) and XL495 (PKMYT1 inhibitor) DCs toward potential IND filings in 2024  |
| Preclinical / Discovery | ✓ Advance up to five new development candidates across multiple modalities / mechanisms of small molecules and biologics  |
Q&A Session
Third Quarter 2023 Financial Results

Nasdaq: EXEL
Financial Appendix
## Non-GAAP Financial Highlights: Q3’23
*(in millions, except per share amounts)*

<table>
<thead>
<tr>
<th></th>
<th>Q3’22</th>
<th>Q2’23</th>
<th>Q3’23</th>
<th>YoY Delta</th>
<th>QoQ Delta</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total revenues</strong></td>
<td>$411.7 M</td>
<td>$469.8 M</td>
<td>$471.9 M</td>
<td>+15%</td>
<td>+0%</td>
</tr>
<tr>
<td><strong>Cost of goods sold</strong></td>
<td>$15.3 M</td>
<td>$17.7 M</td>
<td>$18.8 M</td>
<td>+23%</td>
<td>+6%</td>
</tr>
<tr>
<td><strong>R&amp;D expenses</strong></td>
<td>$182.4 M</td>
<td>$223.0 M</td>
<td>$320.1 M</td>
<td>+76%</td>
<td>+44%</td>
</tr>
<tr>
<td><strong>SG&amp;A expenses</strong></td>
<td>$94.1 M</td>
<td>$126.4 M</td>
<td>$110.1 M</td>
<td>+17%</td>
<td>-13%</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>$291.8 M</td>
<td>$367.1 M</td>
<td>$449.0 M</td>
<td>+54%</td>
<td>+22%</td>
</tr>
<tr>
<td><strong>Other income, net</strong></td>
<td>$9.4 M</td>
<td>$22.5 M</td>
<td>$23.4 M</td>
<td>+148%</td>
<td>+4%</td>
</tr>
<tr>
<td><strong>Income tax provision</strong></td>
<td>$27.3 M</td>
<td>$25.0 M</td>
<td>$14.2 M</td>
<td>-48%</td>
<td>-43%</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>$102.0 M</td>
<td>$100.3 M</td>
<td>$32.1 M</td>
<td>-69%</td>
<td>-68%</td>
</tr>
<tr>
<td><strong>Net income per share, diluted</strong></td>
<td>$0.31</td>
<td>$0.31</td>
<td>$0.10</td>
<td>-68%</td>
<td>-68%</td>
</tr>
<tr>
<td><strong>Ending cash and investments</strong></td>
<td>$2,100.2 M</td>
<td>$2,105.4 M</td>
<td>$1,915.1 M</td>
<td>-9%</td>
<td>-9%</td>
</tr>
</tbody>
</table>

*Amounts may not sum due to rounding.

(a) A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.
(b) Amounts reflect non-GAAP adjustment before tax effect.
(c) Cash and investments is composed of cash, cash equivalents, restricted cash equivalents and investments. Since Q2’23, there are no restrictions on cash, cash equivalents and investments.
Collaboration Revenues Detail

(See press release at www.exelixis.com for full details)

Q3’22 – Q3’23 Notes

- Q3’23 cabozantinib royalties to Exelixis of $37.8M

- Genentech collaboration:
  - Q3’23 ex-US COTELLIC® royalties $1.0M
  - Q3’23 US COTELLIC profit share $2.1M

- Significant milestone revenues recognized by quarter:
  - Q2’23: Takeda commercial milestone earned upon achievement of cumulative net sales of $150M
  - No new milestone license revenues recognized in three out of the last five quarters

Amounts may not sum due to rounding.
Ipsen Royalties
(See press release at www.exelixis.com for full details)

Q3’23 Notes

- Q3’23 Ipsen ex-US and ex-Japan cabozantinib franchise net product revenues of $145.4M
- Q3’23 Ipsen royalty to Exelixis of $34.8M
GAAP to Non-GAAP Reconciliation
(in millions, except per share amounts)

Non-GAAP Financial Measures
To supplement Exelixis' financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis uses certain non-GAAP financial measures in this presentation and the accompanying tables. This presentation and the tables that follow present certain financial information on a GAAP and a non-GAAP basis for Exelixis for the periods specified, along with reconciliations of the non-GAAP financial measures presented to the most directly comparable GAAP measures. Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that each of these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare Exelixis' results from period to period, and to identify operating trends in Exelixis' business. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.

These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis' business. Reconciliations between GAAP and non-GAAP results are presented in the tables that follow.

Amounts may not sum due to rounding.

<table>
<thead>
<tr>
<th></th>
<th>Q3'22</th>
<th>Q4'22</th>
<th>Q1'23</th>
<th>Q2'23</th>
<th>Q3'23</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Research and development expenses reconciliation:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Research and development expenses</td>
<td>$198.8</td>
<td>$336.8</td>
<td>$234.2</td>
<td>$232.6</td>
<td>$332.6</td>
</tr>
<tr>
<td>Stock-based compensation expenses&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>$(16.4)</td>
<td>$(10.5)</td>
<td>$(3.3)</td>
<td>$(9.6)</td>
<td>$(12.4)</td>
</tr>
<tr>
<td>Non-GAAP Research and development expenses</td>
<td>$182.4</td>
<td>$326.4</td>
<td>$230.9</td>
<td>$223.0</td>
<td>$320.1</td>
</tr>
<tr>
<td><strong>Selling, general and administrative expenses reconciliation:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Selling, general and administrative expenses</td>
<td>$115.0</td>
<td>$119.3</td>
<td>$131.4</td>
<td>$141.7</td>
<td>$138.1</td>
</tr>
<tr>
<td>Stock-based compensation expenses&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>$(20.9)</td>
<td>$(15.4)</td>
<td>$(13.4)</td>
<td>$(15.3)</td>
<td>$(28.0)</td>
</tr>
<tr>
<td>Non-GAAP Selling, general and administrative expenses</td>
<td>$94.1</td>
<td>$103.9</td>
<td>$118.0</td>
<td>$126.4</td>
<td>$110.1</td>
</tr>
<tr>
<td><strong>Operating expenses reconciliation:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Operating expenses</td>
<td>$329.1</td>
<td>$472.0</td>
<td>$380.0</td>
<td>$392.0</td>
<td>$489.5</td>
</tr>
<tr>
<td>Stock-based compensation - Research and development expenses&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>$(16.4)</td>
<td>$(10.5)</td>
<td>$(3.3)</td>
<td>$(9.6)</td>
<td>$(12.4)</td>
</tr>
<tr>
<td>Stock-based compensation - Selling, general and administrative expenses&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>$(20.9)</td>
<td>$(15.4)</td>
<td>$(13.4)</td>
<td>$(15.3)</td>
<td>$(28.0)</td>
</tr>
<tr>
<td>Non-GAAP Operating expenses</td>
<td>$291.8</td>
<td>$461.1</td>
<td>$363.3</td>
<td>$367.1</td>
<td>$449.0</td>
</tr>
<tr>
<td><strong>Income tax provision</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Income tax provision</td>
<td>$18.8</td>
<td>$(1.3)</td>
<td>$8.3</td>
<td>$19.2</td>
<td>$4.8</td>
</tr>
<tr>
<td>Income tax effect of stock-based compensation - Research and development&lt;sup&gt;(2)&lt;/sup&gt;</td>
<td>3.7</td>
<td>2.4</td>
<td>0.8</td>
<td>2.2</td>
<td>2.9</td>
</tr>
<tr>
<td>Income tax effect of stock-based compensation - Selling, general and administrative&lt;sup&gt;(2)&lt;/sup&gt;</td>
<td>4.8</td>
<td>3.5</td>
<td>3.1</td>
<td>3.6</td>
<td>6.5</td>
</tr>
<tr>
<td>Non-GAAP Income tax provision</td>
<td>$27.3</td>
<td>$4.6</td>
<td>$12.1</td>
<td>$25.0</td>
<td>$14.2</td>
</tr>
</tbody>
</table>
GAAP to Non-GAAP Reconciliation (continued)
(in millions, except per share amounts)

<table>
<thead>
<tr>
<th>Net Income reconciliation:</th>
<th>Q3’22</th>
<th>Q4’22</th>
<th>Q1’23</th>
<th>Q2’23</th>
<th>Q3’23</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP Net Income</td>
<td>$73.2</td>
<td>$(30.2)</td>
<td>$40.0</td>
<td>$81.2</td>
<td>$1.0</td>
</tr>
<tr>
<td>Stock-based compensation - Research and development&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>16.4</td>
<td>10.5</td>
<td>3.3</td>
<td>9.6</td>
<td>12.4</td>
</tr>
<tr>
<td>Stock-based compensation - Selling, general and administrative&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>20.9</td>
<td>15.4</td>
<td>13.4</td>
<td>15.3</td>
<td>28.0</td>
</tr>
<tr>
<td>Income tax effect of the stock-based compensation adjustments&lt;sup&gt;(2)&lt;/sup&gt;</td>
<td>(8.5)</td>
<td>(5.9)</td>
<td>(3.9)</td>
<td>(5.8)</td>
<td>(9.4)</td>
</tr>
<tr>
<td>Non-GAAP Net Income</td>
<td>$102.0</td>
<td>$(10.2)</td>
<td>$52.8</td>
<td>$100.3</td>
<td>$32.1</td>
</tr>
<tr>
<td>Net Income per share, diluted:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Net Income per share, diluted</td>
<td>$0.23</td>
<td>$(0.09)</td>
<td>$0.12</td>
<td>$0.25</td>
<td>$0.00</td>
</tr>
<tr>
<td>Stock-based compensation - Research and development&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>0.05</td>
<td>0.03</td>
<td>0.01</td>
<td>0.03</td>
<td>0.04</td>
</tr>
<tr>
<td>Stock-based compensation - Selling, general and administrative&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>0.06</td>
<td>0.05</td>
<td>0.04</td>
<td>0.05</td>
<td>0.09</td>
</tr>
<tr>
<td>Income tax effect of the stock-based compensation adjustments&lt;sup&gt;(2)&lt;/sup&gt;</td>
<td>(0.03)</td>
<td>(0.02)</td>
<td>(0.01)</td>
<td>(0.02)</td>
<td>(0.03)</td>
</tr>
<tr>
<td>Non-GAAP Net Income per share, diluted</td>
<td>$0.31</td>
<td>$(0.03)</td>
<td>$0.16</td>
<td>$0.31</td>
<td>$0.10</td>
</tr>
</tbody>
</table>

Weighted-average shares used to compute GAAP net income per share, diluted

<table>
<thead>
<tr>
<th></th>
<th>Q3’22</th>
<th>Q4’22</th>
<th>Q1’23</th>
<th>Q2’23</th>
<th>Q3’23</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>325.1</td>
<td>323.3</td>
<td>326.3</td>
<td>327.3</td>
<td>319.2</td>
</tr>
</tbody>
</table>

<sup>(1)</sup> Non-cash stock-based compensation expense used for GAAP reporting in accordance with ASC 718.

<sup>(2)</sup> Income tax effect on the non-cash stock-based compensation expense adjustments.

Amounts may not sum due to rounding.
# Collaboration Revenues

*(in millions)*

<table>
<thead>
<tr>
<th>Partner</th>
<th>Compound</th>
<th>Description</th>
<th>Q3’22</th>
<th>Q4’22</th>
<th>Q1’23</th>
<th>Q2’23</th>
<th>Q3’23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche (Genentech)</td>
<td>COTELLIC</td>
<td>Profit Share &amp; Royalties on Ex-U.S. sales</td>
<td>3.0</td>
<td>3.2</td>
<td>4.0</td>
<td>6.4</td>
<td>3.1</td>
</tr>
<tr>
<td>Partner Royalties</td>
<td>Cabozantinib</td>
<td>Royalties on ex-U.S.</td>
<td>30.3</td>
<td>33.9</td>
<td>32.7</td>
<td>37.4</td>
<td>37.8</td>
</tr>
<tr>
<td><strong>Milestones:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsen</td>
<td>Cabozantinib</td>
<td>Amortization of Milestones Triggered prior to Q1’18</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Ipsen</td>
<td>Cabozantinib</td>
<td>$50M milestone - 1L RCC Approval</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Ipsen</td>
<td>Cabozantinib</td>
<td>$40M milestone - EMA 2L HCC Approval</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Ipsen</td>
<td>Cabozantinib</td>
<td>$2M milestone - Canada MAA Approval, 1st indication (DTC)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ipsen</td>
<td>Cabozantinib</td>
<td>$25M milestone - MAA approval by EMA, tier 2 add'l indication (DTC)</td>
<td>0.1</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Takeda</td>
<td>Cabozantinib</td>
<td>$16M milestone - Japan regulatory filing 2L RCC</td>
<td>0.3</td>
<td>(0.1)</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Takeda</td>
<td>Cabozantinib</td>
<td>$26M milestone - 1st Commercial Sale in Japan - 2L RCC</td>
<td>0.3</td>
<td>(0.1)</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Takeda</td>
<td>Cabozantinib</td>
<td>$15M milestone - 1st Commercial Sale in Japan - 2L HCC</td>
<td>0.1</td>
<td>-</td>
<td>0.1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Takeda</td>
<td>Cabozantinib</td>
<td>$20M milestone - 1st Commercial Sale in Japan - 1L RCC</td>
<td>0.1</td>
<td>-</td>
<td>0.1</td>
<td>0.1</td>
<td>-</td>
</tr>
<tr>
<td>Takeda</td>
<td>Cabozantinib</td>
<td>$11M milestone - Cumulative Net Sales &gt;$150M</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9.8</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Subtotal Milestones</strong></td>
<td></td>
<td></td>
<td>1.7</td>
<td>0.3</td>
<td>1.3</td>
<td>11.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Milestones License revenues</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8.0</td>
<td>-</td>
</tr>
<tr>
<td>Milestones Collaboration services revenues</td>
<td></td>
<td></td>
<td>1.7</td>
<td>0.3</td>
<td>1.3</td>
<td>3.0</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>R&amp;D Reimbursements &amp; Other:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipsen</td>
<td>Cabozantinib</td>
<td>R&amp;D reimbursement and Product Supply</td>
<td>6.1</td>
<td>5.7</td>
<td>2.9</td>
<td>1.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Ipsen</td>
<td>Cabozantinib</td>
<td>$200M Upfront fee</td>
<td>0.4</td>
<td>0.4</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>Takeda</td>
<td>Cabozantinib</td>
<td>R&amp;D reimbursement and Product Supply</td>
<td>2.5</td>
<td>2.1</td>
<td>2.5</td>
<td>2.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Takeda</td>
<td>Cabozantinib</td>
<td>$50M Upfront fee</td>
<td>0.1</td>
<td>-</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Daiichi Sankyo &amp; royalties</td>
<td>MR CS-3150/MINNEBRO</td>
<td></td>
<td>1.1</td>
<td>1.0</td>
<td>1.6</td>
<td>1.0</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Subtotal R&amp;D Reimbursements &amp; Other</strong></td>
<td></td>
<td></td>
<td>10.3</td>
<td>9.1</td>
<td>7.4</td>
<td>5.4</td>
<td>3.7</td>
</tr>
<tr>
<td><strong>Total License revenues</strong></td>
<td></td>
<td></td>
<td>34.4</td>
<td>38.1</td>
<td>38.3</td>
<td>52.7</td>
<td>42.4</td>
</tr>
<tr>
<td><strong>Total Collaboration services revenues</strong></td>
<td></td>
<td></td>
<td>10.9</td>
<td>8.4</td>
<td>7.1</td>
<td>7.5</td>
<td>3.1</td>
</tr>
<tr>
<td><strong>TOTAL COLLABORATION REVENUES</strong></td>
<td></td>
<td></td>
<td>45.3</td>
<td>46.5</td>
<td>45.4</td>
<td>60.2</td>
<td>45.4</td>
</tr>
</tbody>
</table>

Amounts may not sum due to rounding.
Third Quarter 2023
Financial Results

Nasdaq: EXEL